Medical Pharmacology: Chapter: 18 — Antiparkinson's Disease Drugs -- Module: Park-Module 3 — Dyskinesias, Motor Complications, and Advanced Levodopa Management

Chapter: 18 — Antiparkinson's Disease Drugs — Module: Park-Module 3 — Dyskinesias, Motor Complications, and Advanced Levodopa Management
Tier: T2

1. A 74-year-old man with a 15-year history of Parkinson's disease on carbidopa/levodopa 25/100 mg five times daily reports two distinct movement problems: involuntary leg movements that occur as each dose begins to work and again as it wears off, with relative freedom during peak effect; and separate episodes of painful foot cramping that wake him at 4 AM before his first morning dose. His neurologist must address both problems simultaneously. Which of the following correctly identifies the pathophysiological basis of each problem and the management principle that applies to both?

A) Both phenomena reflect excessive peak dopamine receptor stimulation from his high levodopa dose frequency; reducing each individual dose while maintaining five-times-daily dosing will attenuate both the diphasic dyskinesia and the nocturnal foot cramping by lowering peak concentrations throughout the day and night
B) The leg movements represent peak-dose dyskinesia caused by excessive pulsatile D1 stimulation at maximum concentrations, and the foot cramping represents diphasic dystonia at intermediate concentrations; both are managed by adding amantadine, which blocks NMDA receptor-mediated glutamatergic drive at all concentration levels
C) Both phenomena result from insufficient levodopa coverage — the leg movements reflect inadequate dopaminergic tone during dose transitions causing indirect pathway disinhibition, and the foot cramping reflects overnight off-state; both are managed by increasing total daily levodopa dose and extending dose frequency into the overnight period
D) The leg movements represent diphasic dyskinesia occurring at intermediate levodopa concentrations during ascending and descending dose phases, requiring strategies that minimize concentration fluctuations; the foot cramping represents off-period dystonia from the overnight levodopa nadir, requiring extension of dopaminergic coverage through the sleep period — these are mechanistically distinct problems requiring targeted interventions rather than a single dose adjustment
E) The leg movements and foot cramping both represent forms of off-period dystonia occurring at different points in the dose cycle; both are managed by converting to an extended-release carbidopa/levodopa formulation that eliminates trough periods throughout the 24-hour cycle

ANSWER: D

Rationale:

Option D is correct. This patient has two co-existing but mechanistically distinct levodopa-related movement disorders that require separate targeted interventions. The involuntary leg movements occurring at dose onset and offset with relative freedom at peak represent diphasic dyskinesia — a movement disorder triggered at intermediate plasma levodopa concentrations during the rising (beginning-of-dose) and falling (end-of-dose) phases of each dose cycle, with the characteristic dyskinesia-improvement-dyskinesia pattern. The management principle for diphasic dyskinesia is to minimize inter-dose concentration fluctuations, which can involve more continuous delivery approaches, COMT inhibitor addition to reduce trough depth, or ultimately device-aided continuous delivery. The early morning foot cramping occurring hours after the last evening dose at the overnight levodopa nadir represents off-period dystonia — a distinct phenomenon reflecting insufficient dopaminergic stimulation causing sustained dystonic contractions, requiring extension of levodopa coverage through the sleep period, typically with controlled-release carbidopa/levodopa at bedtime or addition of a bedtime dopamine agonist. Treating both with a single adjustment would be an error: reducing the individual dose to address the diphasic component would worsen the off-period dystonia by deepening the overnight trough, while simply increasing overnight levodopa coverage would not address the intermediate-concentration mechanism of diphasic dyskinesia.

Option A: Option A is incorrect; the foot cramping is not caused by peak dopamine stimulation — it occurs at the overnight nadir when plasma levodopa is negligible, representing insufficient rather than excessive dopaminergic stimulation. Reducing individual doses would worsen the overnight off-period dystonia.
Option B: Option B is incorrect; the leg movements do not represent peak-dose dyskinesia — their occurrence at dose onset and offset with freedom at peak is specifically the defining pattern of diphasic dyskinesia, not PDD. Amantadine is the primary treatment for peak-dose dyskinesia and does not address the concentration-fluctuation mechanism of diphasic dyskinesia.
Option C: Option C is incorrect; the leg movements do not reflect inadequate dopaminergic tone — diphasic dyskinesia occurs because of an abnormal response at intermediate concentrations, not because concentrations are too low. Increasing total daily levodopa dose is not the correct intervention for diphasic dyskinesia.
Option E: Option E is incorrect; foot cramping at 4 AM represents off-period dystonia, not diphasic dyskinesia — these are distinct phenomena, and the leg movements represent diphasic dyskinesia, not a second form of off-period dystonia. Extended-release carbidopa/levodopa has modest evidence for wearing-off but does not reliably eliminate the intermediate-concentration triggering of diphasic dyskinesia.

2. A 70-year-old man with advanced Parkinson's disease has both 4 hours of daily off-time and functionally limiting peak-dose dyskinesias despite optimized oral therapy. His neurologist notes that these two problems appear pharmacologically contradictory — more levodopa reduces off-time but worsens dyskinesia, and less levodopa reduces dyskinesia but worsens off-time. She proposes levodopa-carbidopa intestinal gel infusion as a solution that can reduce both simultaneously. Which of the following best explains the mechanistic basis by which a single intervention can address both wearing-off and dyskinesia at the same time?

A) LCIG reduces both problems by delivering a higher total daily levodopa dose than is achievable orally, saturating dopamine receptors continuously and thereby eliminating the sensitization-driven hyperresponsiveness that causes dyskinesia while also ensuring that plasma concentrations never fall below the motor threshold
B) LCIG eliminates the peak-to-trough plasma levodopa concentration oscillations that are the shared pharmacokinetic driver of both complications: the troughs cause wearing-off by allowing plasma concentrations to fall below the motor threshold, and the peaks and their pulsatile character drive the receptor occupancy swings that sustain the striatal sensitization underlying dyskinesia; by replacing intermittent oral dosing with near-continuous jejunal delivery, LCIG addresses both failure modes through a single pharmacokinetic correction
C) LCIG reduces off-time by delivering levodopa with higher bioavailability than oral tablets, and reduces dyskinesia by co-delivering a proprietary carbidopa concentration that is higher than achievable with oral formulations, providing greater peripheral decarboxylase inhibition that attenuates the peak striatal dopamine concentration per dose
D) LCIG addresses wearing-off through continuous levodopa delivery and addresses dyskinesia through its osmotic vehicle, which contains a low-concentration NMDA receptor antagonist that is co-absorbed from the jejunal mucosa and provides baseline antidyskinetic glutamatergic blockade independent of the levodopa component
E) LCIG reduces both complications through the same mechanism as dopamine agonists — providing a pharmacodynamic baseline of continuous D2 receptor stimulation — but with greater potency because levodopa-derived dopamine stimulates both D1 and D2 receptors simultaneously, producing more complete basal ganglia circuit normalization than receptor-selective agonists

ANSWER: B

Rationale:

Option B is correct. The continuous dopaminergic stimulation (CDS) hypothesis provides the unified mechanistic explanation for why a single intervention — converting from pulsatile oral dosing to near-continuous jejunal delivery — can simultaneously reduce both wearing-off and dyskinesia. These two complications share a common pharmacokinetic root: the oscillating plasma levodopa concentration profile produced by intermittent oral dosing. The troughs of this profile cause wearing-off when plasma concentrations fall below the motor threshold, producing periods of inadequate dopaminergic stimulation. The peaks — and more precisely, the repeated swings from near-saturation to near-zero receptor occupancy — drive the pulsatile D1 receptor stimulation that sustains the molecular sensitization (deltaFosB accumulation, AMPA/NMDA receptor upregulation) underlying dyskinesia. By delivering levodopa and carbidopa continuously into the proximal jejunum via the PEG-J pump, LCIG eliminates both the troughs and the pulsatile peaks, replacing the oscillating profile with a near-steady plasma concentration. This simultaneously removes the wearing-off trigger and attenuates the receptor occupancy swings that perpetuate sensitization — addressing both problems through the same pharmacokinetic correction. The pivotal LCIG trial demonstrated approximately 4 hours of off-time reduction with parallel dyskinesia reduction, confirming this dual benefit.

Option A: Option A is incorrect; LCIG does not work by delivering a higher total daily dose to saturate receptors continuously. Continuous receptor saturation at supraphysiological concentrations would worsen rather than improve dyskinesia by maximizing the pulsatile drive. The benefit is from stabilizing concentrations within the therapeutic window, not from maximizing them.
Option C: Option C is incorrect; LCIG does not have higher bioavailability than oral levodopa in the sense described — its advantage is bypassing gastric emptying variability to achieve more consistent absorption, not intrinsically higher bioavailability. The carbidopa concentration in LCIG is not a proprietary formulation delivering uniquely high peripheral decarboxylase inhibition.
Option D: Option D is incorrect; the LCIG vehicle does not contain an NMDA receptor antagonist. There is no co-absorbed glutamatergic blocking agent in the intestinal gel formulation — the antidyskinetic effect results from stabilizing the levodopa concentration profile, not from a separate pharmacological additive.
Option E: Option E is incorrect; LCIG does not work through the same mechanism as dopamine agonists. Levodopa is a precursor converted to dopamine, not a receptor agonist; its benefit from continuous delivery is pharmacokinetic stabilization, not pharmacodynamic baseline receptor occupation in the manner of a long-acting agonist such as pramipexole extended-release.

3. A 76-year-old man with Parkinson's disease and levodopa-induced dyskinesias has a creatinine clearance of 28 mL/min. He is also taking ondansetron 8 mg twice daily for nausea and has a baseline QTc of 462 ms on ECG. His neurologist wishes to start amantadine for dyskinesia management. Which of the following best integrates the relevant pharmacological considerations to guide prescribing in this patient?

A) Amantadine can be initiated at the standard dose of 100 mg twice daily because its renal dose adjustment threshold of 15 mL/min has not been reached; the QTc prolongation risk of ondansetron is relevant only for intravenous formulations and does not apply to oral dosing, making the combination safe at standard doses
B) Amantadine should be avoided entirely in this patient because his creatinine clearance of 28 mL/min falls below the threshold for safe use, and no dose adjustment protocol exists that would permit its administration in patients with stage 3b chronic kidney disease receiving serotonin receptor antagonists
C) Amantadine can be started at full dose because its antidyskinetic mechanism — NMDA receptor antagonism — does not involve cardiac ion channels and therefore carries no intrinsic QTc prolongation risk regardless of co-medications or baseline QTc values
D) Amantadine's QTc prolongation risk is additive with ondansetron's, but this interaction is clinically manageable by spacing the two medications 6 hours apart, which prevents simultaneous peak plasma concentrations and eliminates the pharmacodynamic interaction at cardiac ion channels
E) Two simultaneous risks require management: amantadine accumulation from renal impairment (CrCl 28 mL/min falls in the range requiring every-other-day dosing or avoidance) prolongs its half-life and raises plasma concentrations that increase both neuropsychiatric and QTc toxicity, and the additive QTc prolongation from combining amantadine with ondansetron at a baseline QTc of 462 ms creates a risk of torsades de pointes that must be weighed against the dyskinesia benefit before prescribing

ANSWER: E

Rationale:

Option E is correct. This patient presents two independent but compounding pharmacological risks that must be integrated before prescribing amantadine. First, his creatinine clearance of 28 mL/min falls in the range of 15–29 mL/min, for which the amantadine prescribing guidance specifies every-other-day dosing or avoidance — not simply a once-daily dose reduction. At CrCl below 30 mL/min, amantadine's elimination is so severely impaired that even once-daily dosing may allow progressive accumulation, substantially raising plasma concentrations and amplifying concentration-dependent toxicities. Second, amantadine carries a recognized QTc prolongation risk, and combining it with ondansetron — a 5-HT3 antagonist with well-established QTc prolongation properties — produces additive pharmacodynamic effects at cardiac hERG potassium channels. This patient's baseline QTc of 462 ms (already borderline prolonged at the upper limit of normal) leaves minimal safety margin before reaching the threshold of 500 ms associated with torsades de pointes risk. The compounding of accumulation-driven higher amantadine concentrations with concurrent ondansetron at a baseline-elevated QTc constitutes a clinically significant combined risk requiring explicit benefit-risk deliberation, QTc monitoring, and consideration of alternative antiemetic agents before amantadine is prescribed.

Option A: Option A is incorrect; the renal dose adjustment threshold for amantadine is not 15 mL/min — dose reduction is required beginning at CrCl below 50 mL/min, with every-other-day dosing or avoidance at CrCl 15–29 mL/min. This patient's CrCl of 28 mL/min clearly requires the most conservative dosing. Additionally, oral ondansetron does carry QTc prolongation risk, particularly at higher doses, and the oral/IV distinction is not accurate for QTc risk assessment.
Option B: Option B is incorrect; amantadine is not absolutely contraindicated at CrCl 28 mL/min — it can be used with dose adjustment and careful monitoring. Stating that no adjustment protocol exists misrepresents the established renal dosing framework.
Option C: Option C is incorrect; amantadine does carry a recognized QTc prolongation risk independent of its NMDA receptor mechanism. QTc prolongation from amantadine is attributed to hERG channel effects, not to NMDA receptor antagonism, and this risk is not negated by the drug's primary pharmacological target.
Option D: Option D is incorrect; pharmacodynamic QTc interactions are determined by the concurrent plasma concentrations of both drugs and cannot be eliminated by staggering doses 6 hours apart — both drugs have half-lives that maintain therapeutic plasma concentrations well beyond 6 hours, so temporal separation does not prevent overlapping cardiac ion channel effects.

4. A pharmacologist asks a resident to explain why amantadine reduces levodopa-induced dyskinesia by connecting the molecular sensitization events in the striatum to the pharmacological mechanism of the drug. Which of the following most accurately traces the complete chain from the molecular changes underlying dyskinesia to the rationale for NMDA receptor antagonism as a therapeutic target?

A) Years of pulsatile D1 receptor stimulation drive progressive deltaFosB accumulation in direct pathway medium spiny neurons, which transcriptionally upregulates AMPA receptor GluA1 and NMDA receptor NR2B subunits; these sensitized neurons then require concurrent corticostriatal glutamatergic input through the upregulated NMDA and AMPA receptors to generate the full dyskinetic motor output — amantadine's uncompetitive open-channel NMDA blockade reduces this permissive glutamatergic drive, attenuating dyskinesia expression without eliminating the dopaminergic motor benefit that depends on D1 receptor signaling rather than NMDA receptor activity
B) DeltaFosB accumulation in indirect pathway medium spiny neurons upregulates D2 receptor expression, increasing indirect pathway sensitivity to levodopa and producing excessive GPe inhibition of the STN; amantadine blocks NMDA receptors on STN neurons, reducing their excitatory output to the GPi and normalizing thalamocortical drive to produce antidyskinetic benefit
C) Pulsatile D1 stimulation causes DARPP-32 dephosphorylation at Thr-34, which activates protein phosphatase 1 and drives deltaFosB degradation; the resulting depletion of deltaFosB reduces inhibitory tone on glutamate receptor gene transcription, leading to NMDA receptor overexpression that amantadine reverses by competitive displacement of glutamate at the NR2 binding site
D) DeltaFosB accumulation increases the expression of presynaptic dopamine transporter (DAT) protein in the remaining nigrostriatal terminals, causing more rapid dopamine reuptake that paradoxically steepens the concentration decline after each dose peak; amantadine inhibits DAT to slow this reuptake and flatten the post-peak concentration curve, reducing the sensitization-driving oscillation
E) Chronic D1 receptor stimulation causes receptor internalization and downregulation, reducing the density of functional D1 receptors on direct pathway medium spiny neurons; the resulting supersensitivity to any remaining receptor stimulation is mediated through NMDA receptor co-activation, and amantadine reduces this supersensitivity by competitively blocking the glutamate site and preventing co-activation

ANSWER: A

Rationale:

Option A is correct. The chain from molecular sensitization to therapeutic target is: (1) years of pulsatile, non-physiological D1 receptor stimulation — driven by the extreme receptor occupancy swings of oral levodopa dosing in the setting of depleted presynaptic buffering capacity — activate the Gs/cAMP/PKA/DARPP-32 cascade repeatedly, driving progressive accumulation of the stable deltaFosB isoform in direct pathway medium spiny neurons (MSNs); (2) deltaFosB transcriptionally upregulates AMPA receptor GluA1 subunits and NMDA receptor NR2B subunits, increasing these neurons' sensitivity to both dopaminergic and glutamatergic inputs; (3) these sensitized direct pathway MSNs cannot, however, generate the full dyskinetic motor output on dopaminergic drive alone — they require concurrent glutamatergic input from the corticostriatal pathway through the upregulated NMDA and AMPA receptors to produce the full hyperresponsive output that manifests as dyskinesia; (4) this glutamatergic input acts permissively — it enables dyskinesia expression in already-sensitized neurons rather than being the primary sensitizing signal; (5) amantadine's uncompetitive open-channel NMDA blockade reduces this permissive corticostriatal glutamatergic drive in a use-dependent fashion proportional to pathological channel activation, attenuating dyskinesia without blocking the D1 receptor-mediated dopaminergic signaling responsible for on-state motor benefit.

Option B: Option B is incorrect; deltaFosB accumulation is centered on direct pathway D1-expressing MSNs, not indirect pathway D2-expressing neurons. The mechanism described — indirect pathway D2 upregulation causing GPe inhibition of STN with amantadine acting on STN NMDA receptors — misidentifies both the cellular locus of sensitization and the site of amantadine's antidyskinetic action.
Option C: Option C is incorrect; pulsatile D1 stimulation causes DARPP-32 phosphorylation at Thr-34 (not dephosphorylation), which inhibits PP1 and sustains downstream signaling driving deltaFosB accumulation — the option inverts the phosphorylation state. Amantadine is also an uncompetitive open-channel blocker, not a competitive displacer of glutamate at the NR2 binding site.
Option D: Option D is incorrect; deltaFosB accumulation does not increase DAT expression in presynaptic terminals. DAT upregulation as a mechanism causing steeper post-peak dopamine decline is not an established pathway in LID pathophysiology, and amantadine's primary antidyskinetic mechanism is NMDA receptor antagonism, not DAT inhibition.
Option E: Option E is incorrect; chronic D1 stimulation in the LID context does not primarily cause receptor downregulation producing supersensitivity through reduced receptor density — the sensitization is a postsynaptic transcriptional change, not a receptor number change. Amantadine is also an uncompetitive open-channel blocker, not a competitive antagonist at the glutamate site.

5. A 68-year-old woman with Parkinson's disease continues to have 2 hours of daily wearing-off despite shortening her levodopa dosing interval to five times daily. Her neurologist adds entacapone 200 mg with each dose. After 6 weeks her wearing-off has improved but remains clinically significant. Rasagiline 1 mg once daily is then added. Which of the following best explains why the addition of rasagiline provides further wearing-off reduction through a mechanism that is genuinely complementary to — rather than redundant with — entacapone?

A) Rasagiline and entacapone act on the same enzymatic target — catechol-O-methyltransferase — but at different tissue locations; entacapone inhibits peripheral COMT in the bloodstream while rasagiline inhibits central COMT in the striatum, so their combined inhibition provides complete blockade of levodopa's O-methylation throughout the body
B) Entacapone and rasagiline both extend the plasma levodopa half-life through complementary peripheral mechanisms — entacapone by blocking O-methylation and rasagiline by blocking oxidative deamination of levodopa in the gut wall — producing additive pharmacokinetic prolongation of the levodopa plasma concentration curve
C) Entacapone extends the duration of each levodopa dose through a peripheral pharmacokinetic mechanism — blocking COMT-mediated O-methylation of levodopa in the circulation, which slows its plasma clearance and broadens the therapeutic concentration window; rasagiline acts through a distinct central pharmacodynamic mechanism — inhibiting MAO-B in the striatum, which slows the oxidative catabolism of dopamine after its synthesis and release, extending the effective duration of each dose's central effect without altering plasma levodopa pharmacokinetics
D) Entacapone and rasagiline both inhibit dopamine catabolism but through different metabolic pathways — entacapone blocks COMT-mediated conversion of dopamine to 3-methoxytyramine in the striatum, while rasagiline blocks MAO-B-mediated conversion to DOPAC — providing complementary blockade of the two major dopamine catabolic routes in the CNS
E) Rasagiline provides additional wearing-off reduction not through a pharmacokinetic mechanism but through neuroprotection — by inhibiting MAO-B-mediated oxidative stress in nigrostriatal neurons, rasagiline partially restores presynaptic dopamine terminal function over weeks of treatment, increasing the endogenous dopamine buffering capacity and reducing the dose-by-dose oscillations that cause wearing-off

ANSWER: C

Rationale:

Option C is correct. Entacapone and rasagiline address wearing-off through mechanisms that operate at entirely different pharmacological levels, making their combination genuinely additive rather than redundant. Entacapone is a peripherally acting COMT inhibitor: it blocks the O-methylation of levodopa to 3-O-methyldopa (3-OMD) in the peripheral circulation, reducing plasma levodopa clearance and extending its plasma half-life. The result is a broader, flatter plasma levodopa concentration curve per dose — the therapeutic concentration window is prolonged, reducing the depth and duration of wearing-off troughs at the pharmacokinetic level. Rasagiline is a selective, irreversible MAO-B inhibitor acting centrally in the striatum: it inhibits the oxidative deamination of dopamine to dihydroxyphenylacetic acid (DOPAC) in striatal neurons and glia, slowing the rate at which levodopa-derived dopamine is catabolized after synthesis and release. This extends the effective duration of each dose's central dopaminergic effect — the same amount of dopamine is active at postsynaptic receptors for longer because it is degraded more slowly. Rasagiline does not substantially alter plasma levodopa pharmacokinetics. The two agents therefore act on different substrates (levodopa vs. dopamine), at different anatomical locations (peripheral circulation vs. CNS striatum), through different enzymatic mechanisms (COMT vs. MAO-B), producing complementary prolongation of the levodopa dose effect at sequential steps in the dopaminergic pathway.

Option A: Option A is incorrect; rasagiline does not inhibit COMT — it inhibits MAO-B. COMT and MAO-B are entirely distinct enzymes. Rasagiline has no COMT-inhibitory activity.
Option B: Option B is incorrect; rasagiline does not block oxidative deamination of levodopa in the gut wall — MAO-B inhibition by rasagiline acts on dopamine in the CNS striatum, not on levodopa in the gastrointestinal tract. Levodopa is not a primary MAO-B substrate.
Option D: Option D is incorrect; entacapone acts peripherally on levodopa in the circulation, not centrally on dopamine in the striatum. Blocking COMT-mediated conversion of dopamine to 3-methoxytyramine is the central action of tolcapone (which has limited CNS penetrance), not entacapone, which is peripherally restricted.
Option E: Option E is incorrect; rasagiline's established clinical mechanism for reducing wearing-off is MAO-B inhibition extending central dopamine availability, not neuroprotection restoring presynaptic terminal function. The neuroprotective hypothesis for rasagiline was investigated but not confirmed as the basis for its clinical wearing-off benefit in the relevant trials.

6. A 72-year-old man has been taking carbidopa/levodopa 25/100 mg three times daily for 6 years with stable motor control and no dyskinesias. Over the past 3 months, at the same unchanged dose, he has begun to develop choreiform movements of his trunk and arms 45 minutes after each dose that resolve as the dose wears off. No medication changes have been made. Which of the following best explains why dyskinesias have now emerged at a dose that was previously well tolerated?

A) Levodopa accumulates in the CNS with long-term use, and after 6 years the total CNS levodopa burden has exceeded the threshold at which NMDA receptor sensitization is irreversibly triggered, producing dyskinesia that will persist even if the dose is now reduced
B) Long-term carbidopa co-administration progressively upregulates peripheral aromatic amino acid decarboxylase, increasing the fraction of each oral dose converted to dopamine before crossing the blood-brain barrier and effectively increasing CNS levodopa delivery per dose over time without any change in the prescribed amount
C) Tolerance to levodopa's therapeutic effects develops after 5–7 years, requiring higher doses to achieve the same motor benefit; the relative levodopa excess at the previous dose now produces dyskinesia because the motor threshold has risen while the dyskinesia threshold has not
D) Progressive nigrostriatal degeneration has continued to reduce dopaminergic terminal density over the 6 years of treatment; as terminal density has fallen below a critical threshold, the presynaptic buffering capacity that previously moderated synaptic dopamine fluctuations per dose has been sufficiently lost that the same oral levodopa dose now produces peak receptor occupancy swings large enough to sustain the molecular sensitization cascade — the dose has not changed, but the disease has progressed to the point where that dose generates pathologically pulsatile receptor stimulation
E) Six years of levodopa therapy has produced progressive D1 receptor downregulation through receptor internalization; the reduced receptor density causes each surviving receptor to be occupied for a longer fraction of the dose cycle at the same levodopa concentration, creating a pharmacodynamically equivalent increase in peak stimulation intensity that crosses the dyskinesia threshold

ANSWER: D

Rationale:

Option D is correct. The emergence of peak-dose dyskinesia at an unchanged levodopa dose after years of well-tolerated therapy is a clinically important and mechanistically instructive phenomenon explained by the progressive loss of presynaptic buffering capacity. In the early years of levodopa therapy, even as nigrostriatal degeneration continues, sufficient dopaminergic terminal density remains to buffer the synaptic dopamine fluctuations produced by each oral dose: vesicular storage absorbs peaks during absorption and releases stored dopamine during troughs, moderating the receptor occupancy oscillation. As terminal density progressively falls with ongoing neurodegeneration, this buffering capacity erodes. When terminal loss crosses a critical threshold — which varies by patient depending on disease severity and rate of progression — the same oral dose that previously produced a moderated, tolerable receptor occupancy profile now produces extreme swings from near-saturation to near-zero. These extreme pulsatile oscillations are sufficient to drive and sustain the molecular sensitization cascade (pulsatile D1 activation → DARPP-32/deltaFosB accumulation → AMPA/NMDA upregulation) that manifests as dyskinesia. The dose has not changed; the disease has progressed to the point where that dose generates pathologically pulsatile receptor stimulation. This mechanism explains why dyskinesia risk is more strongly predicted by disease duration and severity than by levodopa dose, and why patients who have been on stable doses for years can develop dyskinesias as their disease advances.

Option A: Option A is incorrect; levodopa does not accumulate in the CNS with chronic use — its CNS concentration is entirely determined by its plasma concentration at each point in time, which is governed by its short half-life. There is no progressive CNS accumulation over years.
Option B: Option B is incorrect; carbidopa does not progressively upregulate peripheral AADC over time — it inhibits AADC acutely with each dose. Chronic carbidopa co-administration does not produce an upregulation that increases effective CNS levodopa delivery per dose.
Option C: Option C is incorrect; the concept of levodopa tolerance in PD relates to wearing-off and motor fluctuations from receptor sensitization changes, not to a rising motor threshold that causes relative excess at a previously adequate dose. The motor threshold does not rise independently of the dyskinesia threshold in the manner described.
Option E: Option E is incorrect; D1 receptor downregulation from chronic stimulation would reduce rather than effectively increase stimulation intensity per receptor. The mechanism described — reduced receptor density causing each receptor to be occupied longer — inverts the pharmacological consequence of downregulation and is not the established explanation for late-emerging dyskinesia.

7. A patient with Parkinson's disease is prescribed amantadine extended-release (Gocovri) 274 mg for levodopa-induced dyskinesias. Due to a misunderstanding of the instructions, he takes the capsule each morning upon awakening rather than at bedtime. He reports that his dyskinesias are not well controlled and that he is experiencing significant difficulty sleeping and episodes of confusion in the early morning hours. Which of the following best explains the pattern of adverse effects and reduced efficacy produced by this dosing error, based on the pharmacokinetic design of the formulation?

A) Morning dosing produces a flat plasma concentration profile throughout the day because the extended-release mechanism requires gastric acid activation that is highest in the fasted morning state, generating near-continuous amantadine exposure that saturates NMDA receptors tonically and paradoxically reduces their use-dependent blocking efficacy during peak dyskinesia periods
B) Gocovri taken in the morning produces peak plasma amantadine concentrations during the overnight sleep hours rather than during waking hours; high amantadine concentrations during sleep cause insomnia and nocturnal confusion — the adverse effects the bedtime schedule is specifically designed to minimize by keeping concentrations low overnight — while the daytime waking period when dyskinesias are most prevalent coincides with the low-concentration trough of the rising curve, explaining inadequate antidyskinetic efficacy
C) Morning dosing increases the rate of amantadine absorption by co-administration with the first levodopa dose of the day, producing a pharmacokinetic interaction in which levodopa competitively inhibits amantadine's intestinal uptake via the large neutral amino acid transporter, reducing peak amantadine concentrations and impairing antidyskinetic efficacy
D) Taking Gocovri in the morning rather than at bedtime does not alter its pharmacokinetic profile because extended-release mechanisms are independent of circadian timing; the reported adverse effects reflect an idiosyncratic reaction to the higher amantadine dose rather than a predictable consequence of the altered dosing schedule
E) Morning dosing causes the extended-release capsule to be exposed to peak gastric motility, accelerating drug release and converting the pharmacokinetic profile from extended-release to immediate-release kinetics, producing a high peak concentration in the morning followed by a rapid decline that mirrors an immediate-release dose rather than the intended sustained profile

ANSWER: B

Rationale:

Option B is correct. Gocovri's pharmacokinetic design is explicitly time-dependent relative to the sleep-wake cycle. When taken at bedtime as prescribed, the sustained-release mechanism produces low plasma amantadine concentrations during the overnight sleep period — minimizing the neuropsychiatric adverse effects of amantadine (insomnia, nocturnal confusion, hallucinations) that are most problematic during sleep — with a rising concentration profile through the early morning and waking hours that delivers antidyskinetic drug exposure during the period of peak levodopa-related motor activity. When the patient takes Gocovri in the morning instead, this temporal relationship is inverted: peak plasma concentrations now occur during the overnight sleep period (approximately 12–16 hours after morning dosing, based on the extended-release profile), producing exactly the high nocturnal amantadine concentrations that the bedtime schedule is designed to avoid — explaining the insomnia and early morning confusion. Conversely, daytime waking hours now correspond to the low-concentration rising phase of the profile, providing inadequate antidyskinetic exposure during the period when dyskinesias are most clinically relevant — explaining the poor dyskinesia control. This case illustrates that the antidyskinetic and adverse effect profiles of Gocovri are both predictably determined by the timing of dosing relative to the sleep-wake cycle, not merely by the total dose.

Option A: Option A is incorrect; morning dosing does not produce a flat profile from gastric acid activation. The extended-release mechanism of Gocovri is not dependent on gastric acid activation, and tonic NMDA receptor saturation reducing use-dependent efficacy is not how amantadine's pharmacology works — use-dependent block is enhanced, not reduced, by higher concentrations.
Option C: Option C is incorrect; levodopa and amantadine are not transported by the same intestinal transporter. Levodopa is absorbed via the large neutral amino acid transporter (LAT1), while amantadine is absorbed by passive diffusion and cation transporters — there is no pharmacokinetic competition between them at intestinal uptake.
Option D: Option D is incorrect; the pharmacokinetic profile of Gocovri is absolutely dependent on the timing of the dose relative to the circadian cycle, as the release and subsequent plasma concentration profile unfolds over 12–18 hours from the time of ingestion. The adverse effects are not idiosyncratic — they are a predictable and mechanistically explainable consequence of the inverted dosing schedule.
Option E: Option E is incorrect; gastric motility at the time of ingestion does not convert extended-release to immediate-release kinetics. The Gocovri formulation's extended-release mechanism is engineered into the capsule matrix and is not disrupted by normal fasted or fed gastric motility patterns.

8. A 68-year-old woman on levodopa-carbidopa intestinal gel (LCIG) infusion for 14 months undergoes routine laboratory monitoring. Results show: plasma homocysteine 42 µmol/L (reference <15), methylmalonic acid (MMA) 0.52 µmol/L (reference <0.40), serum vitamin B12 210 pg/mL (low-normal), and serum folate normal. She has no neurological symptoms yet. Which of the following best integrates the laboratory findings to identify the mechanism of the metabolic abnormality and the appropriate clinical response?

A) The elevated homocysteine and MMA both reflect folate deficiency from jejunal malabsorption caused by the LCIG infusion catheter disrupting normal proximal intestinal folate uptake; since serum folate is normal, the deficiency is intracellular and requires high-dose folinic acid supplementation to correct
B) The elevated homocysteine with normal folate and low-normal B12 represents a methylation cycle deficiency caused by levodopa's direct inhibition of methionine synthase, independent of carbidopa; LCIG worsens this effect by delivering levodopa continuously rather than intermittently, providing sustained methionine synthase inhibition throughout the day
C) Elevated homocysteine reflects an expected pharmacodynamic effect of LCIG — levodopa is metabolized to S-adenosylhomocysteine via catechol-O-methyltransferase, and the high levodopa load from continuous infusion drives homocysteine accumulation through the transmethylation pathway; MMA elevation is unrelated and reflects subclinical renal impairment
D) Both elevated homocysteine and elevated MMA reflect a single underlying vitamin B12 functional deficiency: B12 as methylcobalamin is required for homocysteine remethylation by methionine synthase (elevated homocysteine when deficient), and as adenosylcobalamin is required for methylmalonyl-CoA mutase activity (elevated MMA when deficient); the low-normal serum B12 confirms subclinical B12 deficiency as the sole cause of both abnormalities, and the appropriate response is B12 supplementation alone with monitoring for neuropathy
E) The carbidopa delivered continuously by LCIG forms hydrazone complexes with pyridoxal phosphate, depleting vitamin B6 cofactor; B6 deficiency impairs cystathionine beta-synthase in the transsulfuration pathway, causing homocysteine accumulation; the elevated MMA identifies co-existing functional B12 deficiency impairing methylmalonyl-CoA mutase independently — together, these findings indicate a combined B6/B12 metabolic deficiency pattern that precedes axonal neuropathy and requires supplementation before neurological symptoms develop

ANSWER: E

Rationale:

Option E is correct. This patient's laboratory pattern — elevated homocysteine, elevated MMA, low-normal B12, and normal folate — represents a combined B6/B12 metabolic deficiency pattern associated with long-term LCIG therapy, identified here at the pre-symptomatic stage through monitoring. The homocysteine elevation is explained by carbidopa's mechanism: carbidopa, a hydrazine derivative delivered in high continuous daily doses by LCIG, forms stable hydrazone complexes with pyridoxal phosphate (PLP), the active form of vitamin B6, depleting the available PLP cofactor. PLP is required by cystathionine beta-synthase, the enzyme that commits homocysteine to the transsulfuration pathway for conversion to cystathionine. When PLP is depleted, transsulfuration is impaired and homocysteine accumulates. The elevated MMA identifies a separate but co-existing functional B12 deficiency: adenosylcobalamin (a B12 form) is the cofactor for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA; when adenosylcobalamin is insufficient, methylmalonyl-CoA accumulates and is hydrolyzed to MMA. The serum B12 of 210 pg/mL is low-normal — in the range where functional tissue B12 deficiency can exist despite borderline-normal serum levels. Critically, these laboratory abnormalities precede axonal neuropathy, representing the pre-clinical metabolic stage of the LCIG-associated neuropathy entity. Appropriate response is B6 supplementation (to replete PLP and restore transsulfuration), B12 supplementation (to address functional deficiency), and ongoing neurological monitoring.

Option A: Option A is incorrect; the pattern of elevated MMA alongside elevated homocysteine with normal folate is not consistent with folate deficiency — folate deficiency elevates homocysteine but not MMA, because folate is required for the methionine synthase remethylation pathway but not for the adenosylcobalamin-dependent MMA pathway. The proposed folinic acid mechanism misidentifies the B6/B12 deficiency pattern.
Option B: Option B is incorrect; levodopa does not directly inhibit methionine synthase. Levodopa is O-methylated by COMT, producing S-adenosylmethionine consumption, but this is a different pathway from direct enzyme inhibition, and it does not explain the MMA elevation, which requires B12 deficiency.
Option C: Option C is incorrect; levodopa O-methylation by COMT does consume S-adenosylmethionine and can contribute to homocysteine accumulation through the transmethylation pathway, but this mechanism does not explain the MMA elevation, which is specifically a marker of functional adenosylcobalamin deficiency — not of COMT activity. Attributing MMA elevation to renal impairment without any indication of renal disease in the stem is unsupported.
Option D: Option D is incorrect; while B12 functional deficiency does account for the elevated MMA — and contributes to the homocysteine elevation — it cannot be the sole cause of this laboratory pattern in a patient on long-term LCIG. The dominant LCIG-specific driver of the homocysteine elevation is carbidopa-mediated B6 depletion: carbidopa forms hydrazone complexes with pyridoxal phosphate, impairing cystathionine beta-synthase in the transsulfuration pathway. Attributing both abnormalities to B12 deficiency alone misses this mechanism and would lead to incomplete management (B12 alone, without B6 repletion), failing to correct the principal cause of the homocysteine elevation.

9. A 65-year-old man with Parkinson's disease undergoes bilateral STN DBS with excellent motor outcome. Per standard post-operative protocol, his carbidopa/levodopa dose is reduced by 50% over 6 weeks to take advantage of the STN stimulation-mediated motor benefit and reduce dyskinesias. Eight weeks post-operatively he develops significant depressed mood, anhedonia, loss of motivation, and passive suicidal ideation. He has no prior psychiatric history. Which of the following best integrates the two pharmacological mechanisms contributing to his depression?

A) Bilateral STN DBS carries a recognized risk of mood and neuropsychiatric adverse effects including depression from stimulation of limbic STN circuits, and the 50% levodopa dose reduction compounds this by withdrawing dopaminergic input to the mesolimbic and mesocortical pathways that support mood regulation — the combination of direct stimulation-related mood effects and dopaminergic withdrawal from the medication reduction produces a more severe depressive syndrome than either factor alone would generate
B) STN DBS causes depression by inadvertently stimulating the substantia nigra pars compacta through current spread, destroying remaining dopaminergic neurons and accelerating disease progression; the levodopa dose reduction then compounds this neuronal loss by reducing the trophic support that exogenous dopamine provides to surviving nigrostriatal cells
C) The depression results entirely from levodopa dose reduction — dopamine is the primary neurotransmitter of mood regulation, and reducing its precursor by 50% predictably produces a depressive syndrome; STN stimulation itself carries no independent mood risk and should not be implicated in this patient's presentation
D) STN DBS-associated depression is caused by the stimulation current spreading to the adjacent subthalamic white matter tracts, disrupting frontal lobe connectivity and producing a disconnection syndrome indistinguishable from major depression; levodopa dose reduction is unrelated because dopaminergic pathways involved in mood are not affected by carbidopa/levodopa at therapeutic doses
E) The depression reflects a nocebo effect from the patient's awareness that STN DBS is associated with mood changes in published literature; the levodopa dose reduction has no pharmacological role in mood because dopamine does not act on limbic circuits at doses used in Parkinson's disease management

ANSWER: A

Rationale:

Option A is correct. This patient's post-operative depression reflects the convergence of two distinct but pharmacologically related mechanisms. First, bilateral STN DBS carries a recognized risk of mood and neuropsychiatric adverse effects, including depression, anxiety, and personality changes. The STN has both motor and limbic subdivisions; stimulation of the limbic STN — or current spread to adjacent limbic structures — can produce direct mood-modulating effects that are independent of motor benefit. The VA/NINDS cooperative study and subsequent clinical series have documented that STN DBS patients show higher rates of depression and mood changes than GPi DBS patients, with some cases of severe post-operative depression requiring psychiatric intervention. Second, the 50% levodopa dose reduction that is standard practice after STN DBS to capitalize on the stimulation-mediated motor improvement has a pharmacodynamic consequence for mood: dopamine, via the mesolimbic and mesocortical pathways (originating from the ventral tegmental area), plays a central role in motivation, reward processing, anhedonia resistance, and mood regulation. In PD patients, exogenous levodopa partially compensates for the dopaminergic denervation of these pathways. A 50% reduction in dopaminergic input can unmask or precipitate depressive symptoms in susceptible individuals — effectively constituting a dopaminergic withdrawal syndrome affecting mood circuits. The convergence of direct stimulation-related limbic effects and dopamine withdrawal from dose reduction produces a more severe depressive syndrome than either mechanism alone. This is a recognized clinical hazard and one reason GPi DBS is preferred in patients with pre-existing mood vulnerabilities.

Option B: Option B is incorrect; STN DBS does not destroy dopaminergic neurons through current spread to the substantia nigra pars compacta. The electrode is placed in the STN, which is dorsal and lateral to the SNc, and current spread sufficient to cause neuronal destruction is not a recognized mechanism of DBS-associated depression.
Option C: Option C is incorrect; STN stimulation does carry an independent mood risk beyond levodopa reduction, as demonstrated by the comparative neuropsychiatric outcomes in the VA/NINDS cooperative study favoring GPi DBS. Attributing the depression entirely to levodopa dose reduction ignores the direct stimulation contribution documented in the literature.
Option D: Option D is incorrect; while STN white matter tract involvement has been proposed as a mechanism for some DBS-related mood changes, attributing it entirely to a disconnection syndrome and dismissing levodopa's role in limbic dopamine circuits is inaccurate. Carbidopa/levodopa-derived dopamine does reach mesolimbic and mesocortical targets at therapeutic doses in PD management.
Option E: Option E is incorrect; the nocebo effect does not produce passive suicidal ideation with anhedonia in a patient with no psychiatric history — this is a clinically significant neuropsychiatric syndrome with pharmacological underpinnings, not a psychogenic response to published risk awareness.

10. A 70-year-old woman with Parkinson's disease takes carbidopa/levodopa 25/100 mg at 7 AM, 11 AM, 3 PM, and 7 PM. She has been troubled by painful early morning foot dystonia at approximately 5 AM that resolves within 30 minutes of her 7 AM dose. Her daytime motor control is excellent. Her neurologist adds entacapone 200 mg specifically with her 7 PM evening dose. Which of the following best explains the pharmacokinetic mechanism by which this targeted addition is expected to reduce her early morning dystonia?

A) Entacapone added to the 7 PM dose inhibits central MAO-B in the striatum during the overnight hours, slowing the catabolism of dopamine synthesized from the evening levodopa dose and maintaining striatal dopamine concentrations above the dystonia threshold through the early morning period
B) Entacapone inhibits peripheral COMT at all four daily doses simultaneously when given with the 7 PM dose, because its irreversible enzyme binding persists for 24 hours and its inhibitory effect accumulates with each additional dose, providing increasing overnight COMT inhibition with each administration
C) Entacapone added to the 7 PM dose blocks peripheral COMT-mediated O-methylation of the evening's levodopa, slowing its plasma clearance and extending the plasma levodopa half-life of that specific dose; this broadens and prolongs the plasma levodopa concentration curve from the 7 PM dose specifically, pushing therapeutic concentrations further into the overnight period and reducing the depth and duration of the pre-dawn levodopa nadir that triggers the dystonic episodes
D) Adding entacapone to the 7 PM dose increases the peak plasma levodopa concentration of the evening dose by preventing its peripheral catabolism, and this higher evening peak produces a longer residual therapeutic tail through stoichiometric proportionality — higher peaks produce proportionally longer duration of action regardless of the elimination half-life
E) Entacapone inhibits COMT in the gut mucosa at the time of the 7 PM dose, increasing the fraction of levodopa absorbed from that dose, and the additional levodopa absorbed is stored in surviving nigrostriatal vesicles overnight, providing a slow-release reservoir of dopamine that prevents the overnight nadir responsible for the dystonic episodes

ANSWER: C

Rationale:

Option C is correct. This question requires integrating the mechanism of COMT inhibition with the pharmacokinetic cause of off-period dystonia to explain why a strategically targeted single-dose COMT inhibitor addition reduces a specific time-point complication. Off-period dystonia at 5 AM reflects the overnight levodopa nadir: the 7 PM dose wears off during the night, plasma levodopa falls below the motor threshold, and insufficient D1/D2 receptor occupancy in the basal ganglia produces sustained dystonic contractions in the foot and calf. The pharmacokinetic correction is to extend the plasma levodopa concentration curve of the last evening dose further into the overnight period. Entacapone added specifically to the 7 PM dose blocks peripheral COMT-mediated O-methylation of the levodopa from that dose, reducing its plasma clearance rate. This extends the plasma levodopa half-life and broadens the concentration-time curve: the drug persists above the therapeutic threshold for longer after the 7 PM dose, reducing the depth of the pre-dawn nadir and pushing the time at which concentrations fall below the dystonia threshold closer to the morning dose time. The key pharmacological insight is that the mechanism is pharmacokinetic — extending the duration of the existing dose's plasma curve — rather than delivering more drug.

Option A: Option A is incorrect; entacapone inhibits peripheral COMT, not central MAO-B. MAO-B inhibition in the striatum is the mechanism of rasagiline and selegiline. Entacapone does not enter the CNS in clinically significant amounts and does not inhibit MAO-B.
Option B: Option B is incorrect; entacapone is a reversible COMT inhibitor — not irreversible — with a duration of action of approximately 2–3 hours per dose that correlates with the levodopa dose interval. It does not produce persistent 24-hour COMT inhibition that accumulates with each dose. The mechanism requires co-administration with each individual levodopa dose to provide inhibition for that dose's absorption and distribution window.
Option D: Option D is incorrect; entacapone's primary pharmacokinetic effect on levodopa is to extend its half-life and broaden the concentration curve, not to substantially increase its peak concentration. While some modest peak elevation occurs, the primary clinical benefit is the prolongation of the therapeutic window, not a stoichiometric proportionality between peak height and duration of action — the latter is not how pharmacokinetics works.
Option E: Option E is incorrect; entacapone acts in the peripheral circulation to slow levodopa catabolism after absorption — it does not act in the gut mucosa to increase the fraction absorbed, and absorbed levodopa is not stored in nigrostriatal vesicles overnight. Levodopa does not create a dopamine reservoir from a single dose; its conversion to dopamine is rapid and its clearance from the brain follows its plasma pharmacokinetics.

11. A 69-year-old woman with advanced Parkinson's disease has been experiencing involuntary leg movements that occur in two distinct windows with each levodopa dose. Her previous physician, believing these to be peak-dose dyskinesias, reduced her individual levodopa dose by 25%. Following the reduction, she reports that the movements are now more severe, occur for longer periods with each dose, and her overall motor function has worsened. Which of the following best identifies the diagnostic error, explains why dose reduction worsened her condition, and identifies the correct management direction?

A) The movements were peak-dose dyskinesias but the dose reduction was insufficient; a further 25% reduction in individual dose combined with an increase in dosing frequency to six times daily would attenuate peak concentrations sufficiently to eliminate dyskinesia while maintaining total daily levodopa exposure
B) The movements were off-period dystonias that the physician misidentified as peak-dose dyskinesias; dose reduction worsened them by deepening the levodopa troughs that trigger dystonia, and the correct management is to extend dopaminergic coverage, not reduce it
C) The movements were peak-dose dyskinesias as diagnosed, but the dose reduction triggered a paradoxical supersensitivity response through acute D1 receptor upregulation; the correct management is to add amantadine while restoring the previous dose to reverse the upregulation before attempting dose reduction again
D) The movements were diphasic dyskinesias — occurring at intermediate concentrations on the rising and falling phases — which the physician misidentified as peak-dose dyskinesias; dose reduction worsened the diphasic pattern by lowering the peak concentration achieved per dose, prolonging the time spent traversing the intermediate dyskinesia-triggering concentration range and reducing the time spent at peak where the patient is relatively dyskinesia-free, and the correct management is to minimize inter-dose concentration fluctuations rather than reduce peak amplitude
E) The movements were levodopa-resistant dyskinesias from non-dopaminergic striatal mechanisms that do not respond to any dose adjustment strategy; the dose reduction was clinically irrelevant to their severity, and the worsening motor function reflects disease progression unrelated to the dose change

ANSWER: D

Rationale:

Option D is correct. This case illustrates one of the most clinically important diagnostic errors in the management of levodopa-related motor complications: misidentifying diphasic dyskinesia as peak-dose dyskinesia and applying the management strategy for PDD — dose reduction — to a condition for which dose reduction is specifically contraindicated. The key diagnostic distinction is timing: the patient's involuntary leg movements occur in two windows per dose cycle (at dose onset and at dose offset), which is the defining pattern of diphasic dyskinesia, not PDD. PDD would occur as a single window at peak concentration with resolution as the dose wears off. When the physician reduced the individual levodopa dose by 25%, the pharmacokinetic consequence was a lower peak concentration per dose. A lower peak means the plasma levodopa concentration curve must traverse the intermediate concentration range — where diphasic dyskinesia is triggered — for a longer time on the ascending phase before either reaching a peak or failing to reach it, and for a longer time on the descending phase. The time spent in the dyskinesia-triggering intermediate range is prolonged, and the time spent at the peak where the patient is relatively dyskinesia-free is reduced or eliminated. The result is exactly what occurred: more severe and longer-duration dyskinesias with each dose, and worse overall motor function because the effective therapeutic peak is no longer reached. The correct management for diphasic dyskinesia is the opposite approach: minimize concentration fluctuations through strategies such as more continuous delivery (LCIG, subcutaneous apomorphine), COMT inhibitor addition to reduce trough depth, or ultimately device-aided continuous delivery for refractory cases.

Option A: Option A is incorrect; these were not PDD, and further dose reduction would worsen diphasic dyskinesia even more severely.
Option B: Option B is incorrect; off-period dystonias occur at the levodopa nadir — before a dose or during the overnight period — not in two movement windows per dose cycle. The two-window-per-dose pattern is specifically diphasic, not dystonic.
Option C: Option C is incorrect; D1 receptor upregulation producing paradoxical supersensitivity after acute dose reduction is not an established mechanism for worsening dyskinesia within weeks, and restoring dose before re-reducing would not be required if the movements were truly PDD.
Option E: Option E is incorrect; the movements are clearly related to levodopa dose changes — they worsened specifically and predictably with dose reduction — indicating they are dose-responsive and not levodopa-resistant.

12. A 67-year-old man with Parkinson's disease and levodopa-induced dyskinesias has been taking amantadine with good dyskinesia control for 14 months. His neurologist considers stopping amantadine to simplify his regimen. The patient asks whether his dyskinesias have been permanently reduced by the amantadine treatment or whether they will return if the drug is stopped. Which of the following best explains the relationship between amantadine's mechanism of action and the persistence of the underlying striatal sensitization?

A) Amantadine permanently reduces dyskinesias because its prolonged NMDA receptor occupation over 14 months has reversed the deltaFosB accumulation in direct pathway medium spiny neurons through a use-dependent receptor normalization process; dyskinesias will not recur if it is stopped because the molecular sensitization has been pharmacologically reversed
B) Amantadine suppresses dyskinesia expression by blocking the permissive glutamatergic drive required for sensitized neurons to generate the full dyskinetic motor output, but it does not address the underlying molecular sensitization — the deltaFosB accumulation and AMPA/NMDA receptor subunit upregulation in direct pathway medium spiny neurons persist throughout treatment; if amantadine is stopped, the glutamatergic gate is reopened and the sensitized neurons can again express the full dyskinetic response to levodopa
C) Amantadine reduces dyskinesias by reversing D1 receptor sensitization through competitive occupancy of D1 receptors during NMDA receptor blockade; because this reversal acts at the receptor level rather than the transcriptional level, the effect is durable for 6–12 months after stopping the drug before dyskinesias gradually re-emerge as sensitization re-establishes
D) Amantadine permanently eliminates the sensitized direct pathway MSN population through excitotoxic protection — by preventing NMDA receptor-mediated calcium entry into these neurons during periods of excessive glutamatergic drive, it protects them from calcium-dependent apoptosis, gradually reducing the number of sensitized neurons to below the threshold required for dyskinesia expression
E) After 14 months of amantadine treatment, deltaFosB has been cleared from direct pathway neurons through normal protein turnover now that its transcriptional drivers have been attenuated by NMDA blockade; stopping amantadine now would be safe because the molecular substrate for dyskinesia has been eliminated, though levodopa-dose reduction should accompany the taper to prevent re-sensitization

ANSWER: B

Rationale:

Option B is correct. Amantadine's mechanism — uncompetitive open-channel NMDA receptor antagonism — acts at the level of the glutamatergic permissive signal that enables sensitized neurons to express dyskinesia, not at the level of the molecular sensitization itself. The underlying sensitization — deltaFosB accumulation in direct pathway medium spiny neurons and the resulting transcriptional upregulation of AMPA receptor GluA1 and NMDA receptor NR2B subunits — represents stable neuroplastic changes that are not reversed by NMDA receptor blockade. These transcriptional changes persist throughout amantadine treatment; the drug suppresses the expression of dyskinesia by reducing the glutamatergic input that the sensitized neurons require to generate the full dyskinetic motor output, but the sensitized state of the neurons themselves remains intact. This is a clinically important distinction: amantadine is a symptomatic treatment of dyskinesia expression, analogous to how anti-epileptic drugs suppress seizure expression without reversing the underlying epileptogenic focus. When amantadine is stopped, the glutamatergic gate is fully reopened, and the sensitized neurons — which have remained sensitized throughout treatment — can again generate the full dyskinetic response to levodopa. Dyskinesias typically recur promptly after amantadine discontinuation for this reason.

Option A: Option A is incorrect; amantadine does not reverse deltaFosB accumulation through any established mechanism. deltaFosB is a stable transcription factor whose accumulation reflects stable neuroplastic changes; NMDA receptor blockade over 14 months does not drive its clearance or reverse the downstream receptor subunit changes.
Option C: Option C is incorrect; amantadine does not occupy D1 receptors and does not reverse D1 receptor sensitization. Its mechanism is NMDA receptor antagonism, not D1 receptor blockade. There is no pharmacological basis for a 6–12-month durability of D1 sensitization reversal after drug discontinuation.
Option D: Option D is incorrect; amantadine does not eliminate sensitized MSNs through excitotoxic protection. Neuroprotective effects of amantadine in PD have been theorized but not established as the mechanism of its antidyskinetic action, and protection from calcium-dependent apoptosis leading to selective elimination of dyskinesia-capable neurons is not how dyskinesia management works.
Option E: Option E is incorrect; deltaFosB is specifically resistant to normal protein turnover — its stability relative to full-length FosB is the molecular basis for its progressive accumulation. NMDA blockade does not accelerate deltaFosB clearance, and it would not be appropriate to stop amantadine based on a presumption that molecular sensitization has been eliminated.

13. A 71-year-old woman with advanced Parkinson's disease has severe diphasic dyskinesias refractory to optimized oral therapy including COMT inhibition, MAO-B inhibition, and amantadine. Her MoCA score is 19/30, indicating mild cognitive impairment, and she has active Crohn's disease affecting the proximal jejunum. She lives alone but has a motivated adult daughter who visits daily and is willing to assist with device management. Which of the following advanced therapy options is most appropriate for this patient, and what is the pharmacological rationale for its selection?

A) Levodopa-carbidopa intestinal gel infusion via PEG-J tube, because it provides the most complete continuous dopaminergic stimulation of all available options and her mild cognitive impairment is a relative rather than absolute contraindication that her daughter's daily support can adequately compensate for
B) Bilateral STN DBS, because her diphasic dyskinesias reflect extreme inter-dose concentration fluctuations best addressed by neuromodulation that eliminates levodopa pharmacokinetics as a variable entirely, and mild cognitive impairment at MoCA 19 falls within the acceptable range for STN DBS candidacy in most movement disorder centers
C) Bilateral GPi DBS, because the direct antidyskinetic effect of GPi stimulation is superior to continuous delivery approaches for diphasic dyskinesias and her cognitive impairment does not worsen the GPi DBS risk-benefit profile in the way it would for STN DBS
D) Conversion to oral levodopa extended-release formulation plus high-dose entacapone with each dose, because this combination achieves near-continuous plasma levodopa concentrations equivalent to intestinal gel infusion without device implantation, and is appropriate for patients in whom invasive approaches are contraindicated by active inflammatory bowel disease
E) Subcutaneous apomorphine infusion via programmable pump, because it provides near-continuous dopaminergic stimulation consistent with the CDS hypothesis rationale for diphasic dyskinesia without requiring jejunal tube placement — making it appropriate despite active Crohn's disease affecting the jejunum — and does not require the level of cognitive function that device programming and LCIG management demand, with the daughter available to manage injection site rotation and pump adjustments

ANSWER: E

Rationale:

Option E is correct. This patient requires continuous dopaminergic stimulation — the mechanistic goal for diphasic dyskinesia, whose management requires eliminating the inter-dose concentration fluctuations that trigger the BOD and EOD dyskinesia windows — but has two factors that exclude or substantially complicate the primary options. Active Crohn's disease affecting the proximal jejunum is a contraindication to LCIG via PEG-J tube: jejunal infusion of the carbidopa/levodopa gel directly into inflamed intestinal mucosa carries risks of worsening inflammation, impaired absorption, peritonitis, and PEG site complications in the setting of active IBD. Mild cognitive impairment (MoCA 19/30) is a recognized risk factor for poor outcomes with DBS, which does not benefit and may worsen cognition, and the level of independent device management required for LCIG is also challenging in patients with cognitive impairment, though caregiver support can mitigate this. Subcutaneous apomorphine infusion addresses both exclusions: it delivers a high-potency full dopamine agonist (apomorphine, acting at D1 and D2 receptors) via a subcutaneous catheter and programmable pump, bypassing the gastrointestinal tract entirely and therefore unaffected by the jejunal Crohn's disease. It provides near-continuous dopaminergic stimulation consistent with the CDS hypothesis. Its device management is less cognitively demanding than LCIG programming, and with the daughter's daily support for injection site rotation and pump management, the cognitive limitation is addressable. It is more readily reversible than DBS or LCIG PEG placement. The principal adverse effects — injection site nodules and necrosis, neuropsychiatric effects, and postural hypotension — require monitoring but are manageable.

Option A: Option A is incorrect; LCIG is specifically contraindicated in this patient by active Crohn's disease affecting the proximal jejunum — the planned infusion site. Proceeding with PEG-J placement in actively inflamed jejunal tissue would carry unacceptable procedural and clinical risks.
Option B: Option B is incorrect; cognitive impairment at MoCA 19/30 is a recognized contraindication to DBS — the established criterion requires absence of significant cognitive impairment. DBS does not benefit and may worsen cognition, and a score of 19/30 on the MoCA indicates more than mild cognitive decline that would generally preclude DBS in most movement disorder center protocols.
Option C: Option C is incorrect; GPi DBS has a somewhat more favorable neuropsychiatric profile than STN DBS, but significant cognitive impairment remains a contraindication for GPi DBS as well — the DBS selection criteria apply to both targets. The description of GPi DBS's antidyskinetic effect as superior to continuous delivery approaches for diphasic dyskinesia also overstates the evidence for GPi DBS specifically targeting diphasic dyskinesia over continuous pharmacological delivery.
Option D: Option D is incorrect; oral ER levodopa plus high-dose entacapone does not achieve plasma levodopa concentrations equivalent to intestinal gel infusion. Oral ER formulations still depend on gastric emptying and provide substantially more variable absorption than direct jejunal delivery. Describing this oral combination as equivalent to LCIG and appropriate when invasive approaches are contraindicated misrepresents the pharmacokinetic evidence.